Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes-Reference-Cited by-同舟云学术

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

Published:2007-10 Issue:1 Volume:139 Page:70-80
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Peggs Karl S.,Sureda Anna,Qian Wendi,Caballero Dolores,Hunter Ann,Urbano-Ispizua Alvaro,Cavet James,Ribera Josep M.,Parker Anne,Canales Miguel,Mahendra Premini,Garcia-Conde Javier,Milligan Donald,Sanz Guillermo,Thomson Kirsty,Arranz Reyes,Goldstone Anthony H.,Alvarez Ivan,Linch David C.,Sierra Jorge,Mackinnon Stephen,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06759.x/fullpdf

Reference39 articles.

1. Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma

2. Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol

3. Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin Lymphoma: Where Do We Stand?

4. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

5. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma;Transplantology;2021-10-03

2. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center;Pathology and Oncology Research;2021-07-27

3. Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies;Blood Cancer Journal;2021-07

4. DNA and modified vaccinia Ankara prime–boost vaccination generates strong CD8 + T cell responses against minor histocompatibility antigen HA‐1;British Journal of Haematology;2021-05-28

5. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies;Therapeutic Advances in Hematology;2020-01